Patents by Inventor Darren R. Williams

Darren R. Williams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10858321
    Abstract: The present invention relates to a composition for inducing cell reprogramming. The indazole derivative compound contained in the composition of the present invention shows an improved biological profile and at the same time can perform efficient cell reprogramming. In addition, unlike conventional compounds (e.g. riversine or BIO) for inducing low-molecular cell reprogramming, the indazole derivative compound of the present invention does not show cytotoxicity and thus is expected to have high growth in the market of cell therapy products when clinically applied. Conventional indazole derivative compounds have never known as a use for cell reprogramming. Compared with conventional indazole derivative compounds, the compound of the present invention has a great cell reprogramming ability while having no or little cytotoxicity.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: December 8, 2020
    Assignee: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Yong Chul Kim, Darren R. Williams, Da Woon Jung, Jung Eun Lee, Shin Ae Seo, Ji Yeon Park
  • Patent number: 9757356
    Abstract: A pharmaceutical composition and a method for preventing or treating a cardiovascular disease are provided. The pharmaceutical composition includes a BIO compound ((2?Z,3?E)-6-bromoindirubin-3?-oxime) or a pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition can specifically act on different types of cells constituting heart tissues, that is, can induce the growth of cardiomyocytes, and can also inhibit proliferation of cardiac fibroblasts and strongly suppress inflammatory mediators in macrophages, thereby significantly recovering the tissues and functions of the heart after the onset of myocardial infarction. Therefore, the pharmaceutical composition can be effectively used to treat various cardiovascular diseases including myocardial infarction.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: September 12, 2017
    Assignee: CHONNAM NATIONAL UNIVERSITY HOSPITAL
    Inventors: Youngkeun Ahn, Yong Sook Kim, Hye-yun Jeong, Darren R. Williams, Da-Woon Jung
  • Publication number: 20170158642
    Abstract: The present invention relates to a composition for inducing cell reprogramming. The indazole derivative compound contained in the composition of the present invention shows an improved biological profile and at the same time can perform efficient cell reprogramming. In addition, unlike conventional compounds (e.g. riversine or BIO) for inducing low-molecular cell reprogramming, the indazole derivative compound of the present invention does not show cytotoxicity and thus is expected to have high growth in the market of cell therapy products when clinically applied. Conventional indazole derivative compounds have never known as a use for cell reprogramming. Compared with conventional indazole derivative compounds, the compound of the present invention has a great cell reprogramming ability while having no or little cytotoxicity.
    Type: Application
    Filed: June 30, 2015
    Publication date: June 8, 2017
    Inventors: Yong Chul KIM, Darren R. Williams, Da Woon JUNG, Jung Eun LEE, Shin Ae SEO, Ji Yeon PARK
  • Patent number: 9254290
    Abstract: The present invention provides a method for screening a diabetes treating agent comprising the following steps: (a) preparing cells inside a culture medium; (b) treating the culture medium with a test substance; (c) treating the result of step (b) with a glucose derivative which is not metabolized; and (d) measuring the glucose derivative which has flowed into the cells, wherein the test substance is determined to be a diabetes treating agent if the test substance accelerates uptake of the glucose derivative in the cells. Therefore, the described pharmaceutical composition, including a triazin-based compound as an active ingredient, can be useful for application in preventing or treating diabetes.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: February 9, 2016
    Assignee: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Darren R. Williams, Da-Woon Jung, Young-Tae Chang
  • Publication number: 20130115642
    Abstract: The present invention provides a method for screening a diabetes treating agent comprising the following steps: (a) preparing cells inside a culture medium; (b) treating the culture medium with a test substance; (c) treating the result of step (b) with a glucose derivative which is not metabolized; and (d) measuring the glucose derivative which has flowed into the cells, wherein the test substance is determined to be a diabetes treating agent if the test substance accelerates uptake of the glucose derivative in the cells. Therefore, the described pharmaceutical composition, including a triazin-based compound as an active ingredient, can be useful for application in preventing or treating diabetes.
    Type: Application
    Filed: July 28, 2011
    Publication date: May 9, 2013
    Applicant: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Darren R. Williams, Da-Woon Jung, Young-Tae Chang